Are specialty drug prices destroying insurers and hurting consumers?: a number of efforts are under way to reduce price pressure
- PMID: 25136254
- PMCID: PMC4123806
Are specialty drug prices destroying insurers and hurting consumers?: a number of efforts are under way to reduce price pressure
Abstract
Organizations are trying to address the high cost of "specialty" medications that treat conditions such as cancer, hepatitis C, and multiple sclerosis. While comprising less than 1% of U.S. prescriptions, these drugs now account for 27% of pharmacy spending.
References
-
- Starner CI, Bowen K, Yang Qiu Y, et al. Association of specialty drug prescription abandonment with increasing member out-of-pocket expense. Prime Therapeutics. 2014 Apr; Available at: http://tinyurl.com/StarnerEtAl. Accessed June 24, 2014.
-
- Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(21):2304–2322. Available at: http://content.onlinejacc.org/article.aspx?articleid=1853961. Accessed June 24, 2014. - PubMed
-
- Campaign for Sustainable Rx Pricing. National Coalition on Health Care. Available at: http://www.csrxp.org. Accessed June 24, 2014.
-
- Howard DH, Conti RM. Are new drugs more expensive than old ones? Trends in the benefit-adjusted launch prices of anticancer drugs, 1995–2013. Presentation at the 2014 American Society of Clinical Oncology Annual Meeting; May 2014; Abstract published in J Clin Oncol 2014:32:5s (suppl; abstr 6525).
LinkOut - more resources
Full Text Sources